YolTech – In Vivo CRISPR/Base Editing Platform Financing

Summary YolTech Therapeutics raised $70M in a Series C financing to expand what is currently one of China’s most advanced in vivo CRISPR and base-editing platforms, with programs spanning sickle cell disease, beta-thalassemia, ATTR, familial hypercholesterolemia, and primary hyperoxaluria type 1. What Happened YolTech announced…